A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Anhye KimJang-Hee HongWonsuk ShinHyounggyoon YooJin Gyu JungJean-Yves ReginsterSungHyun KimYunJu BaeJeeHye SuhSera KimEunKyung LeeStuart L SilvermanPublished in: Expert opinion on biological therapy (2024)
ClinicalTrials.gov: NCT06037395.